Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation –...
Transcript of Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation –...
![Page 1: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/1.jpg)
Meet The ProfessorManagement of Lung Cancer
Professor Tony SK Mok, MDChairman, Department of Clinical Oncology
The Chinese University of Hong KongHong Kong, China
![Page 2: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/2.jpg)
Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
![Page 3: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/3.jpg)
Dr Love — Disclosures
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, AcertaPharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, AgiosPharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGenInc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, SirtexMedical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
![Page 4: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/4.jpg)
Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
![Page 5: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/5.jpg)
Prof Mok — Disclosures
Advisory Committee
AbbVie Inc, ACEA Pharma, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cirina, CStone Pharmaceuticals, Daiichi Sankyo Inc, Fishawack Facilitate Ltd, G1 Therapeutics, Gritstone Oncology, Guardant Health, geneDecode Co Ltd, Hengrui Therapeutics Inc, Hutchison China MediTech Limited, Ignyta Inc, Incyte Corporation, IQVIA, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lunit Inc, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, OrigiMed, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi-Aventis R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation
Consulting Agreements
AbbVie Inc, ACEA Pharma, Alpha Biopharma, Amgen Inc, Amoy Diagnostics Co Ltd, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, CStone Pharmaceuticals, Daiichi Sankyo Inc, Fishawack Facilitate Ltd, Gritstone Oncology, Guardant Health, Hengrui Therapeutics Inc, IgnytaInc, Incyte Corporation, IQVIA, INMED, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lunit Inc, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, OrigiMed, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi-Aventis R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation
Contracted Research
AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, G1 Therapeutics, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, SFJ Pharmaceuticals, Takeda Oncology, Xcovery
![Page 6: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/6.jpg)
We Encourage Clinicians in Practice to Submit Questions
Feel free to submit questions now before the program begins and throughout the program.
![Page 7: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/7.jpg)
Familiarizing Yourself with the Zoom InterfaceHow to answer poll questions
When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.
![Page 8: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/8.jpg)
Upcoming Live Webinars
Meet The Professor: Management of Chronic Lymphocytic Leukemia
Wednesday, October 7, 202012:00 PM – 1:00 PM ET
ModeratorNeil Love, MD
FacultyMitchell R Smith, MD, PhD
Meet The Professor: Immunotherapy and Novel Agents in Gynecologic Cancers
Thursday, October 8, 202012:00 PM – 1:00 PM ET
ModeratorNeil Love, MD
FacultyBrian M Slomovitz, MD
![Page 9: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/9.jpg)
Upcoming Live Webinars
Meet The Professor: Management of Chronic Lymphocytic Leukemia
Wednesday, October 14, 202012:00 PM – 1:00 PM ET
ModeratorNeil Love, MD
FacultyJohn M Pagel, MD, PhD
Meet The Professor: Management of Ovarian Cancer
Thursday, October 15, 202012:00 PM – 1:00 PM ET
ModeratorNeil Love, MD
FacultyKathleen Moore, MD
![Page 10: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/10.jpg)
Upcoming Live Webinars
Addressing Current Questions and Controversies in the Management of Non-Small Cell Lung Cancer with EGFR Mutation
Friday, October 16, 202011:00 AM – 12:00 PM ET
ModeratorNeil Love, MD
FacultyRoy S Herbst, MD, PhDSuresh S Ramalingam, MDHelena Yu, MD
![Page 11: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/11.jpg)
Thank you for joining us!
CME and MOC credit information will be emailed to each participant within 5 days.
![Page 12: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/12.jpg)
![Page 13: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/13.jpg)
Meet The ProfessorManagement of Lung Cancer
Professor Tony SK Mok, MDChairman, Department of Clinical Oncology
The Chinese University of Hong KongHong Kong, China
![Page 14: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/14.jpg)
Meet The Professor Program Participating FacultyJohn V Heymach, MD, PhDProfessor and ChairThoracic/Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer CenterHouston, Texas
Leora Horn, MD, MScIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt University Medical CenterNashville, Tennessee
Corey J Langer, MDDirector of Thoracic OncologyAbramson Cancer CenterProfessor of MedicinePerelman School of MedicineUniversity of PennsylvaniaPhiladelphia, Pennsylvania
Benjamin Levy, MD Associate ProfessorJohns Hopkins School of MedicineClinical DirectorMedical Director, Thoracic Oncology ProgramJohns Hopkins Sidney Kimmel Cancer Centerat Sibley MemorialWashington, DC
Professor Tony SK Mok, MDChairman, Department of Clinical OncologyThe Chinese University of Hong KongHong Kong, China
![Page 15: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/15.jpg)
Meet The Professor Program Participating Faculty
Nathan A Pennell, MD, PhDProfessor, Hematology and Medical OncologyCleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityDirector, Cleveland Clinic Lung Cancer Medical Oncology ProgramCleveland, Ohio
Lecia V Sequist, MD, MPHDirector, Center for Innovation in Early Cancer DetectionMassachusetts General Hospital Cancer CenterThe Landry Family Professor of MedicineHarvard Medical SchoolBoston, Massachusetts
Joel W Neal, MD, PhDAssociate Professor of MedicineDivision of OncologyDepartment of MedicineStanford Cancer InstituteStanford UniversityPalo Alto, California
David R Spigel, MDChief Scientific OfficerProgram DirectorLung Cancer Research Sarah Cannon Research InstituteNashville, Tennessee
Project ChairNeil Love, MDResearch To PracticeMiami, Florida
![Page 16: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/16.jpg)
We Encourage Clinicians in Practice to Submit Questions
You may submit questions using the Zoom Chat
option below
Feel free to submit questions now before the program begins and throughout the program.
![Page 17: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/17.jpg)
Familiarizing Yourself with the Zoom InterfaceHow to answer poll questions
When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.
![Page 18: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/18.jpg)
![Page 19: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/19.jpg)
Meet The ProfessorManagement of Chronic Lymphocytic Leukemia
Wednesday, October 7, 202012:00 PM – 1:00 PM ET
Mitchell R Smith, MD, PhD
ModeratorNeil Love, MD
Faculty
![Page 20: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/20.jpg)
Meet The ProfessorImmunotherapy and Novel Agents
in Gynecologic CancersThursday, October 8, 2020
12:00 PM – 1:00 PM ET
ModeratorNeil Love, MD
Faculty Brian M Slomovitz, MD
![Page 21: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/21.jpg)
Meet The ProfessorManagement of Chronic Lymphocytic Leukemia
Wednesday, October 14, 202012:00 PM – 1:00 PM ET
John M Pagel, MD, PhD
ModeratorNeil Love, MD
Faculty
![Page 22: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/22.jpg)
Meet The ProfessorManagement of Ovarian Cancer
Thursday, October 15, 202012:00 PM – 1:00 PM ET
Kathleen Moore, MD
ModeratorNeil Love, MD
Faculty
![Page 23: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/23.jpg)
Addressing Current Questions and Controversies in the Management of
Non-Small Cell Lung Cancer with EGFR MutationFriday, October 16, 202011:00 AM – 12:00 PM ET
Roy S Herbst, MD, PhDSuresh S Ramalingam, MD
Helena Yu, MD
ModeratorNeil Love, MD
Faculty
![Page 24: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/24.jpg)
Meet The ProfessorManagement of Lung Cancer
Professor Tony SK Mok, MDChairman, Department of Clinical Oncology
The Chinese University of Hong KongHong Kong, China
![Page 25: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/25.jpg)
Gigi Chen, MDDiablo Valley Oncology and Hematology Medical GroupPleasant Hill, California
Laurie Matt-Amaral, MD, MPHAttending PhysicianCleveland Clinic Akron General Medical CenterAkron, Ohio
![Page 26: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/26.jpg)
Meet The Professor with Prof Mok
Module 1: Cases from Drs Matt-Amaral and Chen• Dr Matt-Amaral: A 49-year-old woman, nonsmoker with metastatic adenocarcinoma of the lung – PD-L1: 80%
• Dr Chen: A 72-year-old Asian woman with metastatic NSCLC – History of severe RA, on adalimumab; PD-L1: 50%
• Dr Matt-Amaral: A 66-year-old man with metastatic NSCLC – PD-L1: >50%
• Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung – Del(19) EGFR mutation
• Questions and Comments: Osimertinib resistance mutations; continued osimertinib in patients with brain metastases
• Dr Matt-Amaral: An 84-year-old man with NSCLC and brain metastases – PD-L1: 1%
• Questions and Comments: Clinical implications of the adjuvant osimertinib ADAURA trial
Module 2: Lung Cancer Journal Club with Prof Mok
Module 3: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios
Module 4: Key Papers and Recent Approvals
![Page 27: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/27.jpg)
Case Presentation – Dr Matt-Amaral: A 49-year-old woman, nonsmoker with metastatic adenocarcinoma of the lung – PD-L1: 80%
• Presented to the hospital with hand coordination difficulties
• Two brain masses (see images) and RLL mass identified
• Stage IV adenocarcinoma of the lung, EGFR and ALK: Wildtype, PD-L1: 80%
• Gamma Knife x 2
• Pembrolizumab x 16 à PD à Carboplatin/pemetrexed x 6 à Maintenance pemetrexed x 8 à PD
• Currently, carboplatin/gemcitabine x 9, and ongoing
Questions
• In light of her progressive disease, should we re-run an NGS panel? Would it be reasonable to re-biopsy her?
Dr Laurie Matt-Amaral
![Page 28: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/28.jpg)
Case Presentation – Dr Matt-Amaral: A 49-year-old woman –Brain Masses, with Edema
![Page 29: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/29.jpg)
Case Presentation – Dr Chen: A 72-year-old Asian woman with metastatic NSCLC – History of severe RA, on adalimumab; PD-L1: 50%
• 4/2020: Diagnosed with Stage IV NSCLC, with extensive bony metastases• FoundationOne®: Positive for METD1010H, CDH1, CDKN2A, CDKN2B, MTAP and NF1
- PD-L1: 50%• Palliative RT to RUL, right clavicular bone lesion, right pelvis and femur• Crizotinib• Restaging scan: PD and 2 new small brain metastases
• Capmatinib 400 mg BID- Developing more lower extremity edema
Questions
• If she progresses or cannot tolerate the targeted therapy and also progresses on chemotherapy, would a checkpoint inhibitor be a good option for her?
Dr Gigi Chen
![Page 30: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/30.jpg)
Case Presentation – Dr Matt-Amaral: A 66-year-old man with metastatic NSCLC – PD-L1: >50%
• Lung nodule identified during lung cancer screening (former smoker)
• Scans during surgery planning: Left humeral head lesion
• Biopsy: Metastatic disease, PD-L1 > 50%, no actionable mutations on hotspot panel
• Pembrolizumab x 4 à PD à Carboplatin/pemetrexed/pembrolizumab
• Currently, maintenance pemetrexed/pembrolizumab
Questions
• How would you have approached treatment of his oligometastatic disease?
• After disease progression on pembrolizumab, would you have added the chemotherapy, or stopped the pembrolizumab and continued with chemotherapy alone?
Dr Laurie Matt-Amaral
![Page 31: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/31.jpg)
Case Presentation – Dr Matt-Amaral: A 66-year-old man
Lung Masses Bone Lesion
![Page 32: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/32.jpg)
Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung – Del(19) EGFR mutation
• Work up after skiing accident reveals metastatic adenocarcinoma of the lung- Involvement of the LUL, hilar and mediastinal adenopathy, liver, bone and brain- EGFR del19 mutation
• 8/2018: Osimertinib and zoledronic acid, with initial response systemically and in brain• One year later: PD in bone à SBRT à Zoledronic acid switched to denosumab (severe jaw pain)
- Reverted to zoledronic acid • Currently, scans show multiple new bone progressions, lung disease is stable• GUARDANT: Predominant EGFR exon 19, but also has small amount of EGFR C797s, BRAF V600E,
RET fusion and MET amplification, TP53 and RB1• Carboplatin/pemetrexed
Questions• How would you manage the denosumab-associated jaw pain? Would you have switched back to
zoledronic acid?
Dr Gigi Chen
![Page 33: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/33.jpg)
Osimertinib Adjuvant Therapy in Patients (pts) with Resected EGFR Mutated (EGFRm) NSCLC (ADAURA): Central Nervous System (CNS) Disease RecurrenceTsuboi M et al.ESMO 2020;Abstract LBA1.
![Page 34: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/34.jpg)
ADAURA: Sites of Disease Recurrence
Tsuboi M et al. ESMO 2020;Abstract LBA1.
![Page 35: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/35.jpg)
ADAURA: CNS DFS Events
Tsuboi M et al. ESMO 2020;Abstract LBA1.
![Page 36: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/36.jpg)
ADAURA: CNS DFS in Overall Population
Tsuboi M et al. ESMO 2020;Abstract LBA1.
![Page 37: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/37.jpg)
Questions and Comments: Osimertinib resistance mutations; continued osimertinib in patients with brain metastases
Dr Gigi Chen
![Page 38: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/38.jpg)
Case Presentation – Dr Matt-Amaral: An 84-year-old man with NSCLC and brain metastases – PD-L1: 1%
• Diagnosed with separate LLL and RUL adenocarcinoma lung primaries- PET and bronchoscopy negative for LAD, PD-L1: 1%
• SBRT to both primaries à Observation
• Approximately 1 year later, developed unsteady gait, headaches
• MRI: Multiple brain metastases (largest 3.5-cm)- Gamma Knife x 2
• Carboplatin/pemetrexed/pembrolizumab x 4 à maintenance therapy
Questions
• Would you have treated this patient differently? Instead of SBRT, would you have pushed harder for systemic therapy? Or, due to his age, do you believe radiation therapy was sufficient?
Dr Laurie Matt-Amaral
![Page 39: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/39.jpg)
Questions and Comments: Clinical implications of the adjuvant osimertinib ADAURA trial
Dr Gigi Chen
![Page 40: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/40.jpg)
Osimertinib as Adjuvant Therapy in Patients (pts) with Stage IB–IIIA EGFR Mutation Positive (EGFRm) NSCLC After Complete Tumor Resection: ADAURAHerbst RS et al.ASCO 2020;Abstract LBA5.
Discussion of LBA5Discussant: David R Spigel, MD, FASCO | Sarah Cannon Research Institute
![Page 41: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/41.jpg)
ADAURA Phase III Trial Schema
Herbst RS et al. ASCO 2020;Abstract LBA5.
![Page 42: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/42.jpg)
ADAURA Primary Endpoint: Inv-Assessed DFS(Stage II/IIIA)
Herbst RS et al. ASCO 2020;Abstract LBA5.
![Page 43: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/43.jpg)
ADAURA: DFS by Stage
Herbst RS et al. ASCO 2020;Abstract LBA5.
![Page 44: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/44.jpg)
ADAURA Secondary Endpoint: Inv-Assessed DFS in the Overall Population (Stage IB/II/IIIA)
Herbst RS et al. ASCO 2020;Abstract LBA5.
![Page 45: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/45.jpg)
Meet The Professor with Prof MokModule 1: Cases from Drs Chen and Matt-Amaral
Module 2: Lung Cancer Journal Club with Prof Mok• Timeline of systemic therapy advances in NSCLC• Challenges and opportunities of cfDNA analysis implementation in clinical practice• Osimertinib for leptomeningeal metastases• ATOM study of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI • ALTA-1L trial of brigatinib versus crizotinib for advanced ALK inhibitor-naïve ALK-positive NSCLC• CROWN study of lorlatinib versus crizotinib for advanced ALK inhibitor-naïve ALK-positive NSCLC• Impact of MET inhibitors on survival in NSCLC with MET exon 14 mutations• Asian expert consensus statement on optimal management of Stage III NSCLC • Atezolizumab/bevacizumab/chemotherapy – Subgroup analysis of the IMpower150 trial for patients with EGFR mutations• Relationship between STK11 and KEAP1 mutational status and first-line pembrolizumab efficacy in KEYNOTE-042 • Impact of smoking on the effectiveness of immune checkpoint inhibitors • Pattern and impact of hepatic adverse events with immune checkpoint inhibitors • Safety and feasibility of CRISPR-edited T cells for patients with refractory NSCLC • Acupuncture in the management of chemotherapy-induced peripheral neuropathy
Module 3: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios
Module 4: Key Papers and Recent Approvals
![Page 46: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/46.jpg)
Ang MK, Mok TSK. Respirology 2020;25(1):26-31.
![Page 47: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/47.jpg)
Timeline of the Development of Systemic Therapy in Advanced NSCLC
Ang MK, Mok TSK. Respirology 2020;25(1):26-31.
Crizotinib approved
![Page 48: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/48.jpg)
![Page 49: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/49.jpg)
Liquid Biopsies: Underlying Biology of Nucleic Acid Content Shedding, Detection and Practical Clinical Utility
Rolfo C et al; ISLB. Crit Rev Oncol Hematol 2020;151:102978.
![Page 50: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/50.jpg)
Application of Circulating Biomarkers (Liquid Biopsy)
Rolfo C, et al; ISLB. Crit Rev Oncol Hematol 2020;151:102978.
Application of blood-based liquid biopsy analysis over the span of lung, breast and colorectal cancer. Blood is collected periodically for isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes/organoids. These circulating biomarkers may be applied to guide initial diagnosis, treatment monitoring or planning, prognosis prediction and developing a sequential targeted therapy for patients with diverse solid tumors.
![Page 51: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/51.jpg)
J Thorac Oncol 2020;15(4):637-48.
![Page 52: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/52.jpg)
![Page 53: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/53.jpg)
J Clin Oncol 2020;[Online ahead of print]
J Clin Oncol 2020;[Online ahead of print]
![Page 54: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/54.jpg)
Solomon B et al. ESMO 2020;Abstract LBA2.
Lorlatinib vs Crizotinib in the First-Line Treatment of Patients (pts) with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Results of the Phase III CROWN Study
![Page 55: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/55.jpg)
![Page 56: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/56.jpg)
J Thorac Oncol 2020;15(3):324-43
![Page 57: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/57.jpg)
Lancet Respir Med 2019;7(5):387-401
![Page 58: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/58.jpg)
Cho BC et al. AACR 2020;Abstract CT084.
Relationship between STK11 and KEAP1 Mutational Status and Efficacy in KEYNOTE-042: Pembrolizumab Monotherapy versus Platinum-Based Chemotherapy as First-Line Therapy for PD-L1-Positive Advanced NSCLC
![Page 59: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/59.jpg)
Acta Oncol 2020;59(1):96-100.
![Page 60: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/60.jpg)
Cancer Med 2020;[Online ahead of print]
![Page 61: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/61.jpg)
Nat Med 2020;26(5):732-40
![Page 62: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/62.jpg)
Acupunct Med 2020;[Online ahead of print]
Molassiotis A1, Dawkins B2, Longo R2, Suen LKP1, Cheng HL1, Mok T3, HulmeC2, Yeo W3.
![Page 63: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/63.jpg)
Meet The Professor with Prof MokModule 1: Cases from Drs Chen and Matt-Amaral
Module 2: Lung Cancer Journal Club with Prof Mok• Timeline of systemic therapy advances in NSCLC• Challenges and opportunities of cfDNA analysis implementation in clinical practice• Osimertinib for leptomeningeal metastases• ATOM study of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI • ALTA-1L trial of brigatinib versus crizotinib for advanced ALK inhibitor-naïve ALK-positive NSCLC• CROWN study of lorlatinib versus crizotinib for advanced ALK inhibitor-naïve ALK-positive NSCLC• Impact of MET inhibitors on survival in NSCLC with MET exon 14 mutations• Asian expert consensus statement on optimal management of Stage III NSCLC • Atezolizumab/bevacizumab/chemotherapy – Subgroup analysis of the IMpower150 trial for patients with EGFR mutations• Relationship between STK11 and KEAP1 mutational status and first-line pembrolizumab efficacy in KEYNOTE-042 • Impact of smoking on the effectiveness of immune checkpoint inhibitors • Pattern and impact of hepatic adverse events with immune checkpoint inhibitors • Safety and feasibility of CRISPR-edited T cells for patients with refractory NSCLC • Acupuncture in the management of chemotherapy-induced peripheral neuropathy
Module 3: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios
Module 4: Key Papers and Recent Approvals
![Page 64: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/64.jpg)
Regulatory and reimbursement issues aside, which adjuvant systemic therapy would you generally recommend for a patient with Stage IIBnonsquamous NSCLC and an EGFR exon 19 deletion?
1. Chemotherapy 2. Osimertinib3. Chemotherapy followed by osimertinib4. Other
![Page 65: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/65.jpg)
Pembro/carbo/pem
Pembro/carbo/pem
Pembro/carbo/pem
Pembro/carbo/pem
Pembro/carbo/pem
Pembro
Pembro or hospice
Pembro
Pembro
Pembro/carbo/pem†
Pembro
Pembro
Pembro
Pembro +/- carbo/pem
Pembro
Pembro
Pembro
Pembro
Pembro
Pembro
Age 65 Age 80 Age 65 Age 80
TPS of 10% TPS of 60%
Pembro/carbo/pem Pembro/carbo/pem Pembro Pembro
Pembro/carbo/pem Pembro Pembro* Pembro
Pem = pemetrexed
* If very symptomatic, pembro/carbo/pem; † Likely dose-reduced chemotherapy
Which first-line treatment regimen would you recommend for a patient with metastatic nonsquamous lung cancer, no identified targetable mutations and a PD-L1 TPS of 10%? Of 60%?
![Page 66: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/66.jpg)
Which first-line treatment regimen would you recommend for a patient with metastatic squamous lung cancer, no identified targetable mutations and a PD-L1 TPS of 10%? Of 60%?
Pembro/carbo/ nab-P
Pembro/carbo/ nab-P
Pembro/carbo/ nab-P
Pembro/carbo/ nab-P or P
Pembro/carbo/nab-P
Pembro
Pembro/carbo/nab-P
Pembro/carbo/P
Pembro/carbo/nab-P
Pembro/carbo/P
Pembro
Pembro
Pembro
Pembro +/- carbo/nab-P or P
Pembro
Pembro
Pembro
Pembro
Pembro+/- carbo/nab-P
Pembro
Age 65 Age 80 Age 65 Age 80
TPS of 10% TPS of 60%
Pembro/carbo/nab-P Pembro/carbo/nab-P Pembro Pembro
Pembro/carbo/nab-P Pembro/carbo/nab-P Pembro Pembro
Nab-P = nanoparticle albumin-bound paclitaxel; P = paclitaxel
![Page 67: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/67.jpg)
2 years
2 years
Indefinitely or until PD/toxicity
2 years
2 years
Indefinitely or until PD/toxicity
2 years
Indefinitely or until PD/toxicity
2 years
2 years
Complete clinical response Partial clinical response
Likely 2 years but CR duration dependent Indefinitely or until PD/toxicity
2 years (min) 2 years (min)
PD = progressive disease
How long would you continue treatment for a patient with metastatic NSCLC who is receiving an anti-PD-1/PD-L1 antibody and at first evaluation is tolerating it well and has a…
![Page 68: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/68.jpg)
What is your preferred second-line treatment for a patient with extensive-stage small cell cancer of the lung with metastases and disease progression on chemotherapy/atezolizumab?
1. Topotecan or irinotecan2. Lurbinectedin3. Nivolumab/ipilimumab4. Pembrolizumab5. Nivolumab6. Other
![Page 69: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/69.jpg)
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab
Carbo/etoposide + atezolizumab or durvalumab
Carbo/etoposide + atezolizumab
Age 65 Age 80
Carbo/etoposide + durvalumab Carbo/etoposide + durvalumab
Carbo/etoposide + atezolizumabor durvalumab Carbo/etoposide + durvalumab
Regulatory and reimbursement issues aside, what would be your preferred first-line treatment regimen for a patient with extensive-stage SCLC?
![Page 70: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/70.jpg)
Regulatory and reimbursement issues aside, what would be your preferred first-line treatment regimen for a 65-year-old patient with extensive-stage SCLC and neurologic paraneoplastic syndrome causing moderate to severe proximal myopathy?
Carboplatin/etoposide
Carboplatin/etoposide
Carboplatin/etoposide
Carboplatin/etoposide + atezolizumab or durvalumab
Carboplatin/etoposide
Carboplatin/etoposide + durvalumab
Carboplatin/etoposide + atezolizumab or durvalumab
![Page 71: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/71.jpg)
Regulatory and reimbursement issues aside, what would be your preferred first-line treatment for a 65-year-old patient with extensive-stage SCLC and symptomatic SIADH, in addition to standard treatment for SIADH?
Carboplatin/etoposide + atezolizumab or durvalumab
Carboplatin/etoposide/atezolizumab
Carboplatin/etoposide/atezolizumab
Carboplatin/etoposide + atezolizumab or durvalumab
Carboplatin/etoposide/atezolizumab
Carboplatin/etoposide + durvalumab
Carboplatin/etoposide + atezolizumab or durvalumab
SIADH = syndrome of inappropriate antidiuretic hormone secretion
![Page 72: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/72.jpg)
Meet The Professor with Prof MokModule 1: Cases from Drs Chen and Matt-Amaral
Module 2: Lung Cancer Journal Club with Prof Mok• Timeline of systemic therapy advances in NSCLC• Challenges and opportunities of cfDNA analysis implementation in clinical practice• Osimertinib for leptomeningeal metastases• ATOM study of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI • ALTA-1L trial of brigatinib versus crizotinib for advanced ALK inhibitor-naïve ALK-positive NSCLC• CROWN study of lorlatinib versus crizotinib for advanced ALK inhibitor-naïve ALK-positive NSCLC• Impact of MET inhibitors on survival in NSCLC with MET exon 14 mutations• Asian expert consensus statement on optimal management of Stage III NSCLC • Atezolizumab/bevacizumab/chemotherapy – Subgroup analysis of the IMpower150 trial for patients with EGFR mutations• Relationship between STK11 and KEAP1 mutational status and first-line pembrolizumab efficacy in KEYNOTE-042 • Impact of smoking on the effectiveness of immune checkpoint inhibitors • Pattern and impact of hepatic adverse events with immune checkpoint inhibitors • Safety and feasibility of CRISPR-edited T cells for patients with refractory NSCLC • Acupuncture in the management of chemotherapy-induced peripheral neuropathy
Module 3: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios
Module 4: Key Papers and Recent Approvals
![Page 73: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/73.jpg)
Accelerated Approval of Lurbinectedin for Metastatic SCLCPress Release – June 15, 2020
“On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multicenter open-label, multi-cohort study enrolling 105 patients with metastatic SCLC who had disease progression on or after platinum-based chemotherapy. Patients received lurbinectedin 3.2 mg/m2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity.
The recommended lurbinectedin dose is 3.2 mg/m2 every 21 days.”
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer.
![Page 74: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/74.jpg)
FDA Grants Approval of Pralsetinib for the Treatment of Metastatic NSCLC with RET FusionPress Release – September 7, 2020
“The Food and Drug Administration has approved pralsetinib for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Pralsetinib is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.
The approval is based on the results from the phase I/II ARROW study, in which pralsetinib produced durable clinical responses in people with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement. Pralsetinibdemonstrated an overall response rate (ORR) of 57% ... and complete response (CR) rate of 5.7% in the 87 people with NSCLC previously treated with platinum-based chemotherapy. In the 27 people with treatment-naïve NSCLC, the ORR was 70%, with an 11% CR rate.”
https://www.globenewswire.com/news-release/2020/09/07/2089388/0/en/Roche-announces-FDA-approval-of-Gavreto-pralsetinib-for-the-treatment-of-adults-with-metastatic-RET-fusion-positive-non-small-cell-lung-cancer.html
![Page 75: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/75.jpg)
FDA Approves Selpercatinib for Lung and Thyroid Cancer with RET Gene Mutations or FusionsPress Release — May 8, 2020
“On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib for the following indications:
• Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC);
• Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy;
• Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Efficacy was investigated in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001) in patients whose tumors had RET alterations.”
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions
![Page 76: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/76.jpg)
FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung CancerPress Release — May 6, 2020
“On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
The FDA also approved the FoundationOne CDx assay as a companion diagnostic for capmatinib.
Efficacy was demonstrated in the GEOMETRY mono-1 trial (NCT02414139), a multicenter, non-randomized, open-label, multicohort study enrolling 97 patients with metastatic NSCLC with confirmed MET exon 14 skipping.
The recommended capmatinib dose is 400 mg orally twice daily with or without food.”
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
![Page 77: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/77.jpg)
Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients with HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
Smit EF et al.ASCO 2020;Abstract 9504.
![Page 78: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/78.jpg)
Antibody-Drug Conjugate Trastuzumab Deruxtecan
Smit EF et al. Proc ASCO 2020;Abstract 9504.
![Page 79: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/79.jpg)
DESTINY-Lung01: Efficacy
Smit EF et al. Proc ASCO 2020;Abstract 9504.
Confirmed ORR (by ICR) = 61.9%DCR = 90.5%Median DoR = not reached
• Median PFS = 14.0 mos
![Page 80: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/80.jpg)
DESTINY-Lung01: Treatment-Emergent AEs
Smit EF et al. Proc ASCO 2020;Abstract 9504.
![Page 81: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/81.jpg)
DESTINY-Lung01: AEs of Special Interest – Interstitial Lung Disease
Smit EF et al. Proc ASCO 2020;Abstract 9504.
![Page 82: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/82.jpg)
Meet The ProfessorManagement of Chronic Lymphocytic Leukemia
Wednesday, October 7, 202012:00 PM – 1:00 PM ET
Mitchell R Smith, MD, PhD
ModeratorNeil Love, MD
Faculty
![Page 83: Meet The Professorimages.researchtopractice.com/2020/Meetings/Slides/... · Case Presentation – Dr Chen: A 57-year-old man, never smoker with metastatic adenocarcinoma of the lung](https://reader034.fdocuments.net/reader034/viewer/2022052022/6037fb08e6b9f07953329104/html5/thumbnails/83.jpg)
Thank you for joining us!
CME and MOC credit information will be emailed to each participant within 5 days.